Evidence map›Paper›PMID 40486694›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

US food allergy patients' experiences, priorities, and needs: A qualitative study.

Elisabeth Oehrlein, Silke C Schoch, Omar A Escontrías, Melanie Carver, Sanaz Eftekhari, Jessica Marvel, Chris Leo Pashos, Michael Pistiner, Randall Rutta, Jill Voss and 1 more

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elisabeth OehrleinApplied Patient Experience, LLC, Washington, DC.
Silke C SchochNational Health Council, Washington, DC.
Omar A EscontríasNational Health Council, Washington, DC.
Melanie CarverAsthma and Allergy Foundation of America, Arlington, Va.
Sanaz EftekhariAsthma and Allergy Foundation of America, Arlington, Va.
Jessica MarvelNovartis Pharmaceuticals, East Hanover, NJ.
Chris Leo PashosIndependent Advisor, Boston, Mass.
Michael PistinerMass General for Children, Boston, Mass.
Randall RuttaNational Health Council, Washington, DC.
Jill VossNovartis Pharma AG, Basel, Switzerland.
Joe VandigoApplied Patient Experience, LLC, Washington, DC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Understanding patient experiences with food allergies (FAs) is essential for developing treatments that meet patients' needs and aiding clinicians in optimizing care. Objective: We sought to provide clinicians and researchers with an inclusive view of IgE-mediated FA patients' experiences, including (1) FA's natural history, including signs, symptoms, health system experiences, and diagnosis pathways; (2) the disease's burden and psychosocial impacts on individuals and families; (3) perspectives on treatment attributes, benefits, and clinical trial participation; and (4) topics and resources patients and caregivers seek regarding FAs. Enhanced understanding of these challenges and opportunities can improve personalized care and patient outcomes. Methods: We conducted virtual interviews with 81 US residents with at least 1 physician-confirmed IgE-mediated FA. Interviews lasted up to 60 minutes. All participants were required to self-report a history of severe allergic reactions. Recruitment was via social media, health care providers, and patient advocacy organizations. Results: Most participants had multiple FAs, with peanuts and/or tree nuts (86%) being the most common. Common reaction types were skin/mouth (91%), respiratory (65%), and gastrointestinal (53%). Key diagnosis pathways included seeking urgent/emergency care after severe reactions and discussing moderate symptoms with primary care doctors. Barriers to diagnosis included long allergist wait times, travel, and other commitments. Most participants with epinephrine autoinjectors felt confident using them due to prior training. FA impacts varied, from minor daily disruptions to significant emotional, social, educational, and career challenges, mainly due to allergen avoidance efforts. Most participants (59%) showed an interest in clinical trials, influenced by potential risks and benefits, trial type, location, accessibility, and child willingness. Despite valuing epinephrine autoinjectors, participants noted unmet needs such as inconvenience, high costs, short expiration dates, and shortages. Desired treatment benefits included proactive treatments enabling allergen ingestion without symptoms and more information on FA management. Conclusions: This study offers insights into the diverse needs of IgE-mediated FA patients, highlighting the importance of comprehensive clinician awareness to enhance personalized care, optimize patient experiences, and improve outcomes. Addressing financial barriers and unmet needs through a team approach, clear communication, psychosocial support, and accessible resources is essential.

Indexed as

diagnosis pathwayshealth system experiencesIgE-mediated FAspatient experiencespersonalized carepsychosocial impact

Identifiers

PMID40486694
PMCPMC12140940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.